Aktienanalyse zu YD Bio Ltd (YDES)YDESYD Bio Ltd

YD Bio Ltd is a Taiwan-based company mainly focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization. The Company’s operations include deoxyribonucleic acid (DNA) methylation-based oncology testing programs in the United States. The Company also provides regulated life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology companies, including procurement, logistics coordination, and compliance-focused support for clinical development programs, as well as maintains ocular health product commercialization operations in the United States. The Company’s business model is centered on developing partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer detection. It operates in the Healthcare sector.

Yd Bio Ltd (YDES) is currently trading at $5.92, which is significantly lower than its 52-week high of $25, indicating high volatility and potential for recovery. However, the stock has a low RSI of 43.081, suggesting it is neither overbought nor oversold, and the forward P/E ratio is currently at 0, indicating uncertainty in future earnings. The main risk is the negative net margin of -276.58% for Q4 2024, which raises concerns about profitability.